Medical Identification and Treatment Systems (MITS)
The CBMS-Medical Identification and Treatment Systems (MITS) provides the Warfighter and the Nation with robust, affordable, U.S. Food and Drug Administration (FDA)–approved lifesaving medical countermeasure drug capabilities against chemical, biological, radiological, and nuclear threats. The CBMS-MITS serves as the life cycle product manager for the following fielded products: Convulsant Antidote for Nerve Agents (CANA), Antidote Treatment Nerve Agent Autoinjector (ATNAA), and Soman Nerve Agent Pretreatment Pyridostigmine (SNAPP).
The CBMS-MITS' advanced development efforts include Bioscavenger (BSCAV), Advanced Anticonvulsant System (AAS), Improved Nerve Agent Treatment System (INATS), Inhalation Atropine (IA), and Medical Radiation Countermeasures (MRADC). A future advanced development effort, the Centrally–Acting Nerve Agent Treatment System (CANATS), is preparing for transition to MITS from the technology base.
To rapidly provide the Warfighter and the Nation robust and affordable U.S. Food and Drug Administration (FDA)–approved lifesaving medical countermeasure drug and diagnostic system capabilities against chemical, biological, radiological, and nuclear (CBRN) threats. MITS products range from specific hardware devices, which enable medical personnel to diagnose specific biological warfare agent exposure, to drugs that will prevent or mitigate the actions of chemical, radiological, or nuclear threats.
Last updated: 4/22/2014 2:03:11 PM